Can dopamine D2 receptor antibodies disrupt dopaminergic signaling without proving brain disease?

Dopamine D2-receptor (D2R) autoantibodies have experimentally plausible effects on dopaminergic signaling, but a positive blood test does not by itself establish autoimmune disease of the brain—an especially important distinction when interpreting results in an individual patient.

Mechanistic evidence

• Patient-derived anti-D2R IgG has bound the extracellular N-terminus of human D2R in live cell systems, induced receptor internalization, and reduced D2R surface availability. Fewer accessible surface receptors could plausibly alter neuronal responses to dopamine.
• Experimental studies in Sydenham chorea/PANDAS-related settings also report D2R-associated Gi/o signaling effects and increased dopamine release. These observations support biological plausibility, but cell and animal findings do not demonstrate basal-ganglia dysfunction or symptom causation in people.
• This mechanistic evidence applies principally to antibodies against D2R, not antibodies against dopamine itself. No identified human cohort evidence shows that anti-dopamine antibodies alter dopaminergic function.

Interpreting serum positivity

• Serum reactivity does not show that antibodies cross the blood–brain barrier, are produced within the CNS, bind neuronal targets in vivo, or cause neurologic symptoms.
• A clinically meaningful interpretation requires a compatible neurologic syndrome and validated testing. Paired serum–CSF testing is preferable; antigen-specific intrathecal IgG synthesis (antibody index), inflammatory CSF findings, MRI abnormalities, and objective neurologic features can strengthen evidence for CNS involvement.
• Isolated serum results—particularly low-titer, single-assay, or clinically unexpected positives—need confirmation by another method and phenotype-based interpretation. D2R antibodies have mainly been reported in rare pediatric basal-ganglia encephalitis presentations; serum-only positivity without compatible symptoms or CNS inflammation is not sufficient to diagnose encephalitis.

Bottom line

• Anti-D2R antibodies can plausibly modify dopaminergic signaling through receptor internalization and altered receptor-associated signaling, but serum positivity alone is not evidence that they are pathogenic in the brain or responsible for clinical symptoms.